Avadel Pharmaceuticals (STU:AWK) Change In Receivables : €-19.22 Mil (TTM As of Mar. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Avadel Pharmaceuticals Change In Receivables?

Avadel Pharmaceuticals's change in receivables for the quarter that ended in Mar. 2024 was €-9.76 Mil. It means Avadel Pharmaceuticals's Accounts Receivable increased by €9.76 Mil from Dec. 2023 to Mar. 2024 .

Avadel Pharmaceuticals's change in receivables for the fiscal year that ended in Dec. 2023 was €-9.37 Mil. It means Avadel Pharmaceuticals's Accounts Receivable increased by €9.37 Mil from Dec. 2022 to Dec. 2023 .

Avadel Pharmaceuticals's Accounts Receivable for the quarter that ended in Mar. 2024 was €20.88 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Avadel Pharmaceuticals's Days Sales Outstanding for the three months ended in Mar. 2024 was 76.19.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Avadel Pharmaceuticals's liquidation value for the three months ended in Mar. 2024 was €20.48 Mil.

Avadel Pharmaceuticals Change In Receivables Historical Data

The historical data trend for Avadel Pharmaceuticals's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avadel Pharmaceuticals Change In Receivables Chart

Avadel Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

1.31

8.63

2.47

0.03

-9.37

Avadel Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial															-	0.33	-4.38	-5.41	-9.76

Avadel Pharmaceuticals Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-19.22 Mil.

Avadel Pharmaceuticals (STU:AWK) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Avadel Pharmaceuticals's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	20.877	/	25.004	*	91
=	76.19

2. In Ben Graham's calculation of liquidation value, Avadel Pharmaceuticals's accounts receivable are only considered to be worth 75% of book value:

Avadel Pharmaceuticals's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	81.686	-	82.354	+	0.75 * 20.877	+	0.5 * 10.974
=	20.48

Avadel Pharmaceuticals Change In Receivables Related Terms

Thank you for viewing the detailed overview of Avadel Pharmaceuticals's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Avadel Pharmaceuticals (STU:AWK) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Avadel Pharmaceuticals PLC (STU:AWK) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

AVDL:USA

Address

10 Earlsfort Terrace, Dublin 2, Dublin, IRL, D02 T380

Website

https://www.avadel.com

Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. It identifies, develops, and commercializes branded pharmaceutical products including controlled-release therapeutic products based on its proprietary drug delivery technologies in the United States. The company markets products in both the primary care and sterile injectables markets. Its products portfolio includes Bloxiverz, Vazculep (phenylephrine hydrochloride injection), Akovaz (ephedrine sulfate injection), Karbinal ER (carbinoxamine maleate extended-release oral suspension), AcipHex Sprinkle (rabeprazole sodium), Cefaclor for Oral Suspension, 125 mg/5 mL, 250 mg/5 mL and 375 mg/5 mL, and Flexichamber. Majority of the revenue is derived from the United States.